Every material Form 8-K Pfizer filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pfizer lowered its full-year 2025 revenue guidance to approximately $62.0 billion from $61.0 to $64.0 billion, while reaffirming its 2025 adjusted diluted EPS guidance of $3.00 to $3.15. The company also issued 2026 guidance calling for revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, below the 2025 EPS range, citing a higher expected tax rate and about $1.5 billion of revenue loss from loss of exclusivity.
2025 revenue guidance revised to approximately $62.0 billion from $61.0 to $64.0 billion; 2025 adjusted diluted EPS guidance of $3.00 to $3.15 reaffirmed
2026 adjusted diluted EPS guidance of $2.80 to $3.00, with an effective tax rate of approximately 15% versus approximately 11% in 2025
2026 revenue guidance of $59.5 to $62.5 billion includes about $1.5 billion lower COVID-19 product revenue and about $1.5 billion negative impact from loss of exclusivity
2026 adjusted SI&A and R&D expenses combined expected at $23.0 to $25.0 billion; guidance assumes no share repurchases in 2025 or 2026
Pfizer said on November 13, 2025 that it completed its acquisition of Metsera, Inc. under a merger agreement dated September 21, 2025, as amended November 7, 2025. Metsera holders receive $65.60 per share in cash at closing, an enterprise value of approximately $7.0 billion, plus contingent value rights worth up to $20.65 per share tied to three milestones. The deal adds Metsera's GLP-1-based weight-loss drug candidates to Pfizer's pipeline, but the milestone payments depend on future clinical and regulatory events.
Closing cash consideration of $65.60 per Metsera share, an enterprise value of approximately $7.0 billion
Contingent value rights of up to $20.65 per share in cash across three milestones
Milestones: $4.60 on Phase 3 trial start for MET-097i+MET-233i; $6.40 on FDA approval of MET-097i monotherapy; $9.65 on FDA approval of the combination
Deal completed November 13, 2025 via Mayfair Merger Sub, Inc., a wholly owned subsidiary
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pfizer filing is on SEC EDGAR ↗. 8-K briefs of other companies →